People | July 16, 2022
Enveda appoints Vanitha Sekar as Chief Business Officer
She joins Enveda from Gilead Sciences
She joins Enveda from Gilead Sciences
Advancing to IND-enabling studies with multiple drug candidates
H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.
Up to $30m funding will be provided to advance an innovative vaccine technology that could protect against current and future SARS-CoV-2 variants and other SARS-like Betacoronaviruses.
Supports development and commercialization of complex oral drugs using sensitive molecules, including biologicals
Syngene's collaboration with Zoetis started in 2011
This acquisition is in line with Cipla's strategic imperative to augment the company's wellness portfolio for bringing about a shift from an illness to a wellness mindset.
Novavax’ clinical development program reported no severe allergic reactions
Novavax' vaccine is the first protein-based COVID-19 vaccine authorized in the U.S.
The study demonstrated that patients who received NONS had significant reduction in viral load within 24 hours, which was sustained over seven days of treatment.
Subscribe To Our Newsletter & Stay Updated
